Hypoxia-activated and status-reversing hydrogel platform initiates potent systemic immunity against triple-negative breast cancer
Authors:
- Zhike LiZLZhike Li
- Xianzhou HuangXHXianzhou Huang
- Jin YangJYJin Yang
- Meiling ShenMSMeiling Shen
- Yanjie YouYYYanjie You
- Qinjie WuQWQinjie Wu
- Changyang GongCGChangyang Gong
- 5 May 2025
- journal article
- Published by Elsevier in Chemical Engineering Journal
- Vol. 515
Abstract
No abstract availableFunding Information
- Postdoctoral Research Foundation of China (2023M732444, GZB20230477)
- West China Hospital of Sichuan University (ZYYC23004, 2023HXBH050)
- Sichuan Provincial Science and Technology Support Program (2024NSFSC1736)
- National Natural Science Foundation of China (32301173, 82202976)
- China Postdoctoral Science Foundation
- Sichuan University
- Ningxia Hui Autonomous Region Department of Science and Technology (2023FRD05038)
This publication has 31 references indexed in Scilit:
- Tumor Environment Regression Therapy Implemented by Switchable Prune‐to‐Essence Nanoplatform Unleashed Systemic Immune ResponsesAdvanced Science, 2023
- Antigenicity and adjuvanticity co-reinforced personalized cell vaccines based on self-adjuvanted hydrogel for post-surgical cancer vaccinationBiomaterials, 2023
- Multi‐Targeted and On‐Demand Non‐Coding RNA Regulation Nanoplatform against Metastasis and Recurrence of Triple‐Negative Breast CancerSmall, 2023
- A tactical nanomissile mobilizing antitumor immunity enables neoadjuvant chemo-immunotherapy to minimize postsurgical tumor metastasis and recurrenceActa Pharmaceutica Sinica B, 2022
- Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinomaJournal of Cancer Research and Clinical Oncology, 2020
- Current Landscape of Immunotherapy in Breast CancerJAMA Oncology, 2019
- Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapyCancer Letters, 2019
- Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategiesCritical Reviews in Oncology/Hematology, 2018
- PARP Inhibitors in the Treatment of Triple-Negative Breast CancerClinical Pharmacokinetics, 2017
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013